BioMerieux (FRA:EYWN) SpecialCharges


FRA:EYWN BioMerieux SA FRA:EYWN
84 GF Score
Price €69.30
GF Value €111.02
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is BioMerieux SpecialCharges?

Special Charges only applies to banks.

FRA:EYWN
84GF Score
BioMerieux SA FRA:EYWN
SpecialCharges is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BioMerieux (FRA:EYWN) Overvalued in 2026?

Based on GuruFocus' analysis, BioMerieux stock appears to be undervalued. The current stock price of €69.30 is trading 37.6% below its estimated GF Value™ of €111.02. GuruFocus considers BioMerieux to be Significantly Undervalued.

Key valuation signals for FRA:EYWN:

  • SpecialCharges:
  • GF Value™: €111.02 vs. price of €69.30 (37.6% below fair value)
  • GF Score™: 84/100 with 3 warning signs

No single metric tells the full story. See the FRA:EYWN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioMerieux Business Description

Address Marcy l’Etoile, Lyon, FRA, 69280
BioMérieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (42% of 2024 sales), microbiology (33%), immunoassays (10%), and industrial applications (about 15%). The Americas account for the largest portion of the firm's revenue (40%), followed by Asia-Pacific (27%) and Europe, the Middle East, and Africa (27%). BioMérieux is headquartered in Marcy-l'Étoile, France.
84GF Score

Get the complete analysis for FRA:EYWN

SpecialCharges is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€69.30
Price
€111.02
GF Value